The purpose of this study is to determine whether giving abciximab (ReoPro) to children with sickle cell disease who are hospitalized for acute pain crisis will improve their pain and shorten the time spent in the hospital, when compared with standard supportive care. The study will start in September 2013 and it is expected to be completed in September 2015.

More information: clinicaltrials.gov, ITHANET Clinical Trials